Regeneron Pharmaceuticals, Inc. Is Being Sued For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESS Newswire / February 7, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...
BioSpace3d
Regeneron Misses on Eylea, Dupixent Sales; Issues First-Ever Dividends
Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...
Regeneron’s earnings boosted by more than doubling of U.S. sales of blockbuster eye drug Eylea
Regeneron Pharmaceuticals Inc.’s stock rose 4.9% Tuesday to put it on track for its biggest one-day gain in almost two years, ...
Stocktwits on MSN1d
Regeneron Stock Down 30% Over Past 6 Months: Leerink Sees Buying Opportunity, Retail's On The Same Page
Shares of Regeneron Pharmaceuticals have plunged more than 30% over the past six months, but one Wall Street analyst believes ...
Regeneron Q4 Earnings: Dividend And Dupixent Drive Solid Quarter - Eylea To Strike Back In 2025
Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...
FiercePharma2d
With recent launches and more to come, Amgen's biosimilar business is trending up
After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...
JD Supra2d
Federal Circuit Affirms Preliminary Injunctions in EYLEA® Biosimilar Litigations Against Samsung Bioepis and Formycon
On January 29, 2025, the CAFC issued opinions affirming the preliminary injunctions issued against biosimilars of Regeneron’s EYLEA® ...
ENDPOINTS NEWS2d
Eye­Point shares more mid-stage da­ta for ther­a­py try­ing to com­pete with Re­gen­eron's Eylea
EyePoint's Duravyu meets primary endpoint in Phase 2 DME trial, showing potential to compete with Regeneron's Eylea and Roche ...
Regeneron beats quarterly estimates on eczema drug demand; launches dividend program
Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...
Regeneron Is Playing Defense With Capital Allocation
Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...
Regeneron projects EYLEA HD growth with new approvals and prefilled syringe launch in 2025
Q4 2024 Management View CEO Leonard Schleifer highlighted 10% revenue growth in Q4 2024, attributed to strong performance from Dupixent, Libtayo, and EYLEA HD. He emphasized the acceleration in EYLEA ...